Cytokinetics (CYTK) Announces Early HSR Act Termination in Astellas Merger
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Cytokinetics, Inc. (Nasdaq: CYTK) announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the 2016 amendment to the License and Collaboration Agreement initially executed between Cytokinetics and Astellas Pharma Inc., in 2013 and amended in 2014. In July 2016, the companies expanded the collaboration related to the research, development and commercialization of skeletal muscle activators. With the termination of the applicable waiting period under the HSR Act, the 2016 amendment is deemed effective as of Sept. 26, 2016 and the upfront payment of $65 million from Astellas to Cytokinetics is due and payable within 30 days.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Noah Holdings (NOAH) Announces RMB348M Investment From Sequoia Capital China
- Buckeye Partners (BPL) Enters Agreement to Acquire 50% Stake in VTTI B.V. for $1.15B
- Clayton Williams Energy (CWEI) Enters Agreement to Sell Giddings Area Assets in $400M Deal; Names New COO
Create E-mail Alert Related CategoriesCorporate News, Mergers and Acquisitions
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!